Researchers have discovered that the drug finerenone, commonly used to treat kidney disease, can restore fertility in women with premature ovarian insufficiency (POI)[1]. POI is a condition that affects more than 1% of women and causes loss of ovarian function before the age of 40, which until now was considered irreversible[1]. Finerenone works by reducing fibrosis (scarring and hardening of tissue) in the ovarian stromal tissue, thereby allowing egg development[1]. In experiments on mice, the drug promoted the development of follicles without negative effects on egg quality or the health of the offspring[1]. In a pilot clinical study of 14 women with POI, all patients receiving finerenone (20 mg twice weekly for up to 7 months) developed advanced follicles[3]. Seven patients subsequently produced mature eggs suitable for artificial insemination, and three of them obtained embryos through IVF[3]. The drug is administered in tablet form and has a good safety profile with no serious side effects or risk of fetal harm[2].